WuXi AppTec
A global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
Launch date
Employees
Market cap
€14.2b
Enterprise valuation
€13.3b (Public information from Sep 2024)
Share price
CNY40.53 603259.SS
Shanghai Shanghai (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 16.5b | 22.9b | 39.4b | 40.3b | 39.6b | 43.3b | 48.2b |
% growth | 28 % | 39 % | 72 % | 3 % | (2 %) | 9 % | 11 % |
EBITDA | 4.6b | 7.2b | 12.8b | 14.7b | 14.0b | 15.5b | 16.0b |
% EBITDA margin | 28 % | 32 % | 32 % | 37 % | 35 % | 36 % | 33 % |
Profit | 3.0b | 5.1b | 8.8b | 9.6b | 9.6b | 10.7b | 11.2b |
% profit margin | 18 % | 22 % | 22 % | 24 % | 24 % | 25 % | 23 % |
EV / revenue | 19.3x | 14.9x | 5.9x | 5.1x | 2.6x | 2.2x | 1.9x |
EV / EBITDA | 69.4x | 47.3x | 18.3x | 14.0x | 7.3x | 6.2x | 5.6x |
R&D budget | 693m | 942m | 1.6b | 1.4b | - | - | - |
R&D % of revenue | 4 % | 4 % | 4 % | 4 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.2m | Series A | ||
N/A | $2.2m | Series A | |
N/A | Series B | ||
$17.3m | Series C | ||
$63.0m | Post IPO Equity | ||
N/A | N/A | Post IPO Equity | |
$1.5b | Debt | ||
N/A | $1.0b Valuation: $10.2b 9.6x EV/LTM Revenues 35.9x EV/LTM EBITDA | IPO | |
* | N/A | $1.0b | Post IPO Equity |
Total Funding | €19.7m |
Recent News about WuXi AppTec
EditInvestments analysisEdit
ACQUISITION by WuXi AppTec Jan 2017
exited